The onset of stroke involves many pathophysiological and cellular processes, including edema, cerebral blood barrier disruption, neuroinflammation, immune response, cell death, neuronal remodeling, and spontaneous recovery, etc. Most of the underlying molecular mechanisms are largely unknown, which hinders the identification of new targets and biomarkers and subsequent therapeutic development. Identification and quantification of specific proteins and mRNAs in situ and in brain tissue samples can provide valuable information to elucidate signaling pathways and molecular mechanisms involved in recovery from ischemic brain injury and stroke and aid in the development of therapeutic drugs.
Fig. 1. The expression of TRIM67 decreased after cerebral ischemia-reperfusion injury. (Yu et al., 2023)
Ace Therapeutics provides customers worldwide with reliable services to quantify protein and mRNA expression levels in ischemic brain injury, enabling researchers to gain insight into the complex molecular mechanisms of ischemic stroke. The proteins and genes being tested can be selected according to customer needs. The Ace Therapeutics's protein and gene analysis workflow is designed to improve processing efficiency, reproducibility, and result accuracy, helping to provide a reliable data foundation for stroke research in shorter time and simpler operations.
We can detect the changes of stroke-related proteins after modeling or after drug administration.
We can detect the changes of stroke-related genes after modeling or after drug administration.
At Ace Therapeutics, we are committed to providing cutting-edge quantitative analysis of stroke-related proteins and mRNAs, enabling researchers to decipher the complexity of stroke pathophysiology and develop effective therapeutic agents. If you are interested in our services, please do not hesitate to contact us!
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.